Dr. Lauchle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave # M-691
San Francisco, CA 94143Phone+1 415-476-3831Fax+1 415-502-5127
Education & Training
University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2002 - 2005- University of California (San Francisco)Residency, Pediatrics, 1998 - 2001
University of Maryland School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2000 - 2026
Clinical Trials
Publications & Presentations
PubMed
- 93 citationsPhase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug
Clinical Cancer Research. 2016-06-15 - 52 citationsPhase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsAntoine Italiano, J. R. Infante, Geoffrey I. Shapiro, Kathleen N. Moore, Patricia LoRusso
Annals of Oncology. 2017-09-01 - 55 citationsPhase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth Blackwood
Clinical Cancer Research. 2017-05-15
Grant Support
- Modeling Multi-Step Leukemogenesis In NF1 And KRAS Mutant MiceNational Cancer Institute2007–2009
- Modeling Multi-Step Leukemogenesis NF1 And KRAS Mutant MiceNational Cancer Institute2006–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
